Status:
COMPLETED
Interest of Nitazoxanide Treatment of Enterocytozoon Bieneusi Intestinal Microsporidiosis
Lead Sponsor:
University Hospital, Clermont-Ferrand
Conditions:
Microsporidiosis Intestinal
Eligibility:
All Genders
18+ years
Brief Summary
Microsporidia are pathogenic fungi mainly responsible for profuse watery diarrhea, requiring management in immunocompromised patients. The main immunocompromised population affected by these infection...
Eligibility Criteria
Inclusion
- With a diagnosis of intestinal infection caused by E. bieneusi between 01/01/2018 and 03/31/2022
- having received treatment with nitazoxanide ("NITAZO" group), or fumagillin ("FUMA" group), or albendazole ("ABZ") or having received no specific treatment but having benefited from an adjustment of the doses of immunosuppressants ("IS" group)
Exclusion
- With a diagnosis of extraintestinal infection
- With a diagnosis of infection by a species other than E. bieneusi
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05417815
Start Date
April 1 2022
End Date
June 1 2022
Last Update
July 27 2022
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Amiens
Amiens, France
2
CHU Besançon
Besançon, France
3
CHU Bordeaux
Bordeaux, France
4
CHU Brest
Brest, France